Sensei Biotherapeutics reports Phase 1 data for SNS-101: 59% tumor reduction in MSS endometrial cancer, well tolerated

Sensei Biotherapeutics, Inc.

Confirmed partial response (59% decrease) in an MSS endometrial cancer patient on SNS-101 plus cemiplimab; remains on study at 30+ weeks.
No dose-limiting toxicities; most AEs grade 1-2; mild cytokine release syndrome at highest dose manageable.
PK profile shows linear elimination and dose-proportional exposure, supporting once-every-3-week dosing.
Tumor regression observed in MSS CRC (27%), pembrolizumab-resistant RCC (18%), and HPV+ head & neck cancer (17%).
Company expects initial dose expansion data and end-of-Phase 1 FDA meeting by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.